SEC Comment Letter 0000000000-24-006750 to Biomea Fusion, Inc. (BMEA)
Biomea Fusion, Inc.
Date: June 12, 2024 · CIK: 0001840439 · Accession: 0000000000-24-006750
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-40335
Letter
United States securities and exchange commission logo June 12, 2024 Franco Valle Principal Financial and Accounting Officer Biomea Fusion, Inc. 900 Middlefield Road, 4th Floor Redwood City, CA 94063 Re:Biomea Fusion, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Filed March 28, 2024 File No. 001-40335 Dear Franco Valle: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2023 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Research and Development Expenses, page 103 1.You disclose, on page 101, that you track direct costs by stage of program, clinical or preclinical. Please address the following:
•Revise your disclosure in future filings to break out clinical costs by program or by indication separately for each period presented. •If you do not track clinical costs on a more granular level, revise your disclosure to explain the reason. •For preclinical costs, revise your disclosure to break out the total amount spent for each period presented. •Provide us with your proposed disclosure. In closing, we remind you that the company and its management are responsible for the
FirstName LastNameFranco Valle Comapany NameBiomea Fusion, Inc. June 12, 2024 Page 2 FirstName LastName Franco Valle Biomea Fusion, Inc. June 12, 2024 Page 2 accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Vanessa Robertson at 202-551-3649 or Tracie Mariner at 202-551-3744 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 12, 2024
Franco Valle
Principal Financial and Accounting Officer
Biomea Fusion, Inc.
900 Middlefield Road, 4th Floor
Redwood City, CA 94063
Re:Biomea Fusion, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
Filed March 28, 2024
File No. 001-40335
Dear Franco Valle:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended December 31, 2023
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Research and Development Expenses, page 103
1.You disclose, on page 101, that you track direct costs by stage of program, clinical or
preclinical. Please address the following:
•Revise your disclosure in future filings to break out clinical costs by program or by
indication separately for each period presented.
•If you do not track clinical costs on a more granular level, revise your disclosure to
explain the reason.
•For preclinical costs, revise your disclosure to break out the total amount spent for
each period presented.
•Provide us with your proposed disclosure.
In closing, we remind you that the company and its management are responsible for the
FirstName LastNameFranco Valle
Comapany NameBiomea Fusion, Inc.
June 12, 2024 Page 2
FirstName LastName
Franco Valle
Biomea Fusion, Inc.
June 12, 2024
Page 2
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Vanessa Robertson at 202-551-3649 or Tracie Mariner at 202-551-3744
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences